Study Title: A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024
 

• Open to Accrual at:
  • University of Illinois Cancer Center
  • University of Wisconsin Carbone Cancer Center
  • University of Rochester
• Closed to Accrual at:
  • Michigan State University Breslin Cancer Center
  • Penn State Cancer Institute
  • Rutgers Cancer Institute of New Jersey
• Learn more:
  • clinicaltrials.gov: NCT03090165
  • Big Ten CRC News Release
• Publications and Presentations:
  • Ongoing Clinical Trials: San Antonio Breast Cancer Symposium 2018

Study Contact: studies@hoosiercancer.org; (317) 921-2050.